Pharmaceutical Risk-Sharing Agreements
- 1 January 2008
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 26 (7) , 551-556
Abstract
Increased spending on pharmaceuticals continues to foster debate over healthcare policy. The increasing costs of bringing products to the market, as well as increased utilization of pharmaceuticals contribute to increased pharmaceutical expenditure; however, appropriate pharmaceutical use can, in certain cases, reduce overall healthcare costs. Nevertheless, the perception of high drug prices still puts pressure on pharmaceutical companies to build confidence in the proposition that their products are worth the additional expense. One potential approach to building this confidence, and maintaining investment incentives, is for the pharmaceutical company to share the risk of a situation in which there is uncertainty about whether the product is effective for the consumer and payer. Such risk-sharing arrangements for pharmaceuticals, like warranties, can be used to signal high quality when product quality is not fully observable. While there may be difficulties in devising such schemes for every product, such risk-sharing plans may become a staple feature of the market in the future.Keywords
This publication has 10 references indexed in Scilit:
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Do new prescription drugs pay for themselves?Journal of Health Economics, 2005
- Pharmaceuticals in U.S. Health Care: Determinants of Quantity and PriceJournal of Economic Perspectives, 2002
- Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPSHealth Affairs, 2001
- Explaining Drug Spending Trends: Does Perception Match Reality?Health Affairs, 2000
- Do (more and better) drugs keep people out of hospitals?1996
- Pricing, Profits, and Technological Progress in the Pharmaceutical IndustryJournal of Economic Perspectives, 1993
- Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActThe Journal of Law and Economics, 1992
- A New Look at the Returns and Risks to Pharmaceutical R&DManagement Science, 1990
- Warranties as Signals under Consumer Moral HazardThe RAND Journal of Economics, 1989